Institutional Repository (UniKL IR)
Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/26307
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSubramaniyan, Vetriselvan-
dc.contributor.authorFuloria, Shivkanya-
dc.contributor.authorDarnal, Hari Kumar-
dc.contributor.authorMeenakshi, Dhanalekshmi Unnikrishnan-
dc.contributor.authorSekar, Mahendran-
dc.contributor.authorRusli Nordin-
dc.contributor.authorChakravarthi, Srikumar-
dc.contributor.authorSathasivam, Kathiresan V.-
dc.contributor.authorKhan, Shah Alam-
dc.contributor.authorWu, Yuan Seng-
dc.contributor.authorKumari, Usha-
dc.contributor.authorSudhakar, Kalvatala-
dc.contributor.authorMalviya, Rishabha-
dc.contributor.authorSharma, Vipin Kumar-
dc.contributor.authorFuloria, Neeraj Kumar-
dc.contributor.author(UniKL RCMP)-
dc.date.accessioned2022-11-21T02:43:25Z-
dc.date.available2022-11-21T02:43:25Z-
dc.date.issued2021-09-
dc.identifier.citationFuloria, S., Fuloria, N., Subramaniyan, V., Darnal, H., Meenakshi, D., Sekar, M., Rusli Nordin, Chakravarthi, S., Sathasivam, K., Khan, S., Wu, Y., Kumari, U., Sudhakar, K., Malviya, R., & Sharma, V. (2021). COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine, 14(9), 401. https://doi.org/10.4103/1995-7645.326253en_US
dc.identifier.issn19957645-
dc.identifier.urihttps://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=9;spage=401;epage=409;aulast=Subramaniyan;type=0-
dc.identifier.urihttp://hdl.handle.net/123456789/26307-
dc.description.abstractIn the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapiesen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.subjectCOVID-19en_US
dc.subjectImmunosuppressionen_US
dc.subjectMucormycosisen_US
dc.subjectPathogenesisen_US
dc.subjectTreatmenten_US
dc.titleCOVID-19-associated mucormycosis and treatmentsen_US
dc.typeOtheren_US
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
COVID-19-associated mucormycosis and treatments.pdf396.58 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.